CXCL13 in laboratory diagnosis of Lyme neuroborreliosis-the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samplesShow others and affiliations
2022 (English)In: European Journal of Clinical Microbiology and Infectious Diseases, ISSN 0934-9723, E-ISSN 1435-4373, Vol. 41, no 1, p. 175-179Article in journal (Refereed) Published
Abstract [en]
The chemokine CXCL13 is used as complement to serology in the diagnostics of Lyme neuroborreliosis (LNB). We evaluated and compared the semi-quantitative, cassette-based ReaScan CXCL13 assay with the quantitative recomBead CXCL13 assay using a collection of 209 cerebrospinal fluid samples. The categorical agreement between results interpreted as negative, grey zone, and positive by the two methods was 87%. The diagnostic sensitivity was higher using the recomBead assay, whereas specificity was higher using ReaScan. Few manual steps, and a short turn-around time with no batching of samples makes the ReaScan CXCL13 assay an attractive complement to serology in the diagnostics of LNB.
Place, publisher, year, edition, pages
Springer, 2022. Vol. 41, no 1, p. 175-179
Keywords [en]
CXCL13, Diagnostics, Lyme neuroborreliosis, ReaScan, recomBead
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-94879DOI: 10.1007/s10096-021-04350-yISI: 000705823200001PubMedID: 34626256Scopus ID: 2-s2.0-85116568394OAI: oai:DiVA.org:oru-94879DiVA, id: diva2:1601889
Funder
European Commission
Note
Funding agency:
Interreg North Sea Region Programme J-No: 38-2-7-19
2021-10-112021-10-112023-12-08Bibliographically approved